Coya Therapeutics Receives FDA Approval for COYA 302 ALS Treatment Trial

Coya Therapeutics announces FDA acceptance of its Investigational New Drug (IND) application for COYA 302, a biologic combination therapy for the treatment of amyotrophic lateral sclerosis (ALS). The FDA's approval enables the initiation of a Phase 2 clinical study to evaluate the efficacy and safety of COYA 302 in ALS patients. The study is a multicenter, double-blind, placebo-controlled trial.